
TABLE OF CONTENTS

HEADS OF AGENCIES – CMDH.....	1
HEADS OF AGENCIES – PAEDIATRIC REGULATION	1
EUROPEAN MEDICINES AGENCY (EMA)	2
NOTICE TO APPLICANTS.....	5
BFARM - PHARMAKOVIGILANZ (SPECIFIC FOR GERMANY)	5
BFARM – MEDIZINPRODUKTE (SPECIFIC FOR GERMANY)	5
PEI - VIGILANZ (SPECIFIC FOR GERMANY)	5
PHARMEUROPA TEXTS FOR COMMENT.....	5

HEADS OF AGENCIES – CMDh

01 August

NEW: Art. 46 AR Repevax, Adacel-Polio, Triaxis-Polio

UPDATE: Member States Recommendations on the Cover Letter for New Applications submitted through MRP/DCP

UPDATE: Cover letter template for renewals

UPDATE: Cover letter for Variation Applications in the Mutual Recognition Procedure

UPDATE: Template cover letter for new applications submitted through MRP/DCP

UPDATE - Overview AR Template (incl. instructions)

UPDATE - D70 Overview AR Template (empty)

NEW - Instructions for RMS when preparing the PAR based on the FAR

NEW - PAR template (empty) - when prepared based on FAR

30 July

NEW - Report from the meeting held on 22-23 July 2025

UPDATE - CMDh statistics 2024

29 July

NEW - European medicines regulatory network's response to nitrosamine impurities in human medicines

HEADS OF AGENCIES – PAEDIATRIC REGULATION

Article 45 work-sharing: *click [here](#)*

EUROPEAN MEDICINES AGENCY (EMA)

Date	Content	Status
04/08/2025	Document: Scientific advice and protocol assistance adopted during the CHMP meeting 21- 24 July 2025	New
01/08/2025	Page: Plasma master file certificates	Updated
01/08/2025	PSUSA: PSUSA/00000830/202411 - periodic safety update report single assessment	New
01/08/2025	PSUSA: PSUSA/00000831/202411 - periodic safety update report single assessment	New
01/08/2025	Medicine: Nuvaxovid	Updated
01/08/2025	Document: Organisation chart: Information Management	Updated
01/08/2025	PSUSA: PSUSA/00010184/202406 - periodic safety update report single assessment	Updated
01/08/2025	Medicine: Blenrep	Updated
01/08/2025	Medicine: Bexsero	Updated
01/08/2025	Medicine: Enjaymo	Updated
01/08/2025	Event: Training session on human variations web-based electronic application form (eAF) for CAPs	New
01/08/2025	Event: Q&A clinic on web-based application form functionalities for CAPs and non-CAPs	New
01/08/2025	Event: Q&A clinic on web-based electronic application form (eAF) functionalities for CAPs and non-CAPs	New
01/08/2025	Medicine: Rybelsus	Updated
01/08/2025	Page: Recommendations on medication errors	Updated
01/08/2025	DHPC: Rybelsus - direct healthcare professional communication (DHPC)	New
01/08/2025	Medicine: Evkeeza	Updated
01/08/2025	Event: Quality Innovation Group (QIG) Listen and Learn Focus Group (LLFG) meeting on personalised medicines	Updated
01/08/2025	Medicine: Vyloy	Updated
01/08/2025	Medicine: Skyrizi	Updated
01/08/2025	Document: Day 80 assessment report - Clinical template with guidance - Rev. 07.25 - Revamp	Updated
01/08/2025	Herbal: Combination: Species diureticae - herbal medicinal product	Updated
01/08/2025	Document: Declaration of interests: Silvy da Rocha Dias	Updated
01/08/2025	Herbal: Fragariae folium - herbal medicinal product	Updated
01/08/2025	Document: List of centrally authorised products with safety-related changes to the product information	Updated
01/08/2025	Event: Training session on human variations web-based electronic Application Form (eAF) for non-CAPs	New
01/08/2025	Herbal: Liquiritiae radix - herbal medicinal product	Updated
01/08/2025	Document: CHMP-CAT - D80-210 Overview to final EPAR - Rev 07.25 Revamp	Updated
01/08/2025	Document: Declaration of interests: Karen Quigley	Updated
01/08/2025	Document: Declaration of interests: Virginia Rojo Guerra	Updated
01/08/2025	Herbal: Cannabis flos - herbal medicinal product	Updated
01/08/2025	Document: Appendix 1: Acceptable intakes established for N-nitrosamines	Updated
01/08/2025	Page: Opinions and letters of support on the qualification of novel methodologies for medicine development	Updated
01/08/2025	Document: Overview of comments received on the draft qualification opinion for Simcyp Simulator	New
01/08/2025	Document: Qualification opinion for Simcyp Simulator	New
31/07/2025	Medicine: Saxenda	Updated

Date	Content	Status
31/07/2025	Document: List of EU Medicines Regulatory Agency Organisation with single and multiple LOC IDs for Product Management Services (PMS) data enrichment - Chapter 2 Annex III	Updated
31/07/2025	PSUSA: PSUSA/00000832/202411 - periodic safety update report single assessment	New
31/07/2025	Medicine: Trulicity	Updated
31/07/2025	Medicine: Delstrigo	Updated
31/07/2025	Medicine: Xofluza	Updated
31/07/2025	Medicine: Reagila	Updated
31/07/2025	Medicine: Xtandi	Updated
31/07/2025	Page: Business hours and holidays	Updated
31/07/2025	Medicine: Tevimbra	Updated
31/07/2025	Document: Highlight report - 14th meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines	New
31/07/2025	Document: IRIS guide to registration and RPIs	Updated
31/07/2025	Page: ICH E6 Good clinical practice - Scientific guideline	Updated
31/07/2025	Medicine: Libmyris	Updated
31/07/2025	Medicine: Trepulmix	Updated
31/07/2025	EU-M4all: Pyramax - opinion on medicine for use outside EU	Updated
31/07/2025	Page: Paediatric-use marketing authorisations	Updated
31/07/2025	Medicine: Lynparza	Updated
31/07/2025	Medicine: Omlyclo	Updated
31/07/2025	Medicine: Kostaive	Updated
31/07/2025	Medicine: Anoro Ellipta (previously Anoro)	Updated
31/07/2025	Medicine: Avtozma	Updated
31/07/2025	Medicine: Sugammadex Piramal	Updated
31/07/2025	Document: List of changes to combined Veterinary Dictionary for Drug Regulatory Activities (VeDDRA) list of clinical terms for reporting suspected adverse events in animal and humans to veterinary medicinal products for 2025	Updated
31/07/2025	Page: EudraVigilance: electronic reporting	Updated
30/07/2025	Page: Cholic acid product-specific bioequivalence guidance	Updated
30/07/2025	Medicine: Vyvgart	Updated
30/07/2025	Page: Dabrafenib product-specific bioequivalence guidance	New
30/07/2025	Medicine: Benlysta	Updated
30/07/2025	Medicine: Emevet	Updated
30/07/2025	Event: EMA Cancer Medicines Forum (CMF) meeting with industry stakeholders on cancer treatment optimisation	New
30/07/2025	Page: Search tips	Updated
30/07/2025	Page: Azacitidine product-specific bioequivalence guidance	New
30/07/2025	Document: Overview of comments received on the “HMA/EMA guidance document on the identification of personal data and commercially confidential information within the structure of the marketing authorisation application (MAA) dossier” - public consultation	New
30/07/2025	Page: Aprepitant product-specific bioequivalence guidance	New
30/07/2025	Medicine: Nemludio	Updated
30/07/2025	Page: Vortioxetine hydrobromide / vortioxetine lactate product-specific bioequivalence guidance	Updated
30/07/2025	Page: Zonisamide product-specific bioequivalence guidance	Updated
30/07/2025	Document: List of medicinal products under additional monitoring	Updated
30/07/2025	Document: List of medicinal products under additional monitoring	Updated

Date	Content	Status
30/07/2025	Document: List of European Union reference dates (EURD) and frequency of submission of periodic safety update reports (PSURs)	Updated
30/07/2025	Page: Paclitaxel product-specific bioequivalence guidance	New
30/07/2025	Page: Emtricitabine/tenofovir disoproxil product-specific bioequivalence guidance	Updated
30/07/2025	Page: Colchicine product-specific bioequivalence guidance	Updated
30/07/2025	Page: Ticagrelor product-specific bioequivalence guidance	Updated
30/07/2025	Page: Emtricitabine / rilpivirine / tenofovir disoproxil product-specific bioequivalence guidance	Updated
30/07/2025	Page: Rilpivirine product-specific bioequivalence guidance	Updated
30/07/2025	Page: List of medicines under additional monitoring	Updated
30/07/2025	Page: Rivaroxaban product-specific bioequivalence guidance	Updated
30/07/2025	Page: Sitagliptin product-specific bioequivalence guidance	Updated
30/07/2025	Page: Tacrolimus granules product-specific bioequivalence guidance	Updated
29/07/2025	Medicine: Xgeva	Updated
29/07/2025	PSUSA: PSUSA/00000375/202410 - periodic safety update report single assessment	New
29/07/2025	PSUSA: PSUSA/00001911/202412 - periodic safety update report single assessment	New
29/07/2025	Page: Fingolimod product-specific bioequivalence guidance	Updated
29/07/2025	Page: Entecavir product-specific bioequivalence guidance	Updated
29/07/2025	Medicine: Eklira Genuair	Updated
29/07/2025	Medicine: Duaklir Genuair	Updated
29/07/2025	Page: Clinical trials in human medicines	Updated
29/07/2025	Page: Website outages and upgrades	Updated
29/07/2025	Event: Workshop on a tailored clinical approach in biosimilar development	New
29/07/2025	Document: Record of data processing activity in the context of selection and recruitment procedures	Updated
29/07/2025	Document: Summary of the Medicine Shortages SPOC Working Party meeting on 17 June 2025	New
29/07/2025	Page: Nitrosamine impurities	Updated
29/07/2025	Document: Report: European medicines regulatory network's response to nitrosamine impurities in human medicines	New
28/07/2025	Medicine: Nubeqa	Updated
28/07/2025	Medicine: Osvyrti	Updated
28/07/2025	Medicine: Iqirvo	Updated
28/07/2025	Medicine: Sephience	Updated
28/07/2025	Medicine: Hukyndra	Updated
28/07/2025	Medicine: Jubereq	Updated
28/07/2025	Document: Start of procedure: Type II variation - Extension of indication under evaluation by the CHMP (20 June 2025 - 24 July 2025)	New
28/07/2025	Document: Start of procedure: Extension of marketing authorisation (20 June 2025 - 24 July 2025)	New
28/07/2025	Event: SPOR and XEVMPD status update webinar	Updated
28/07/2025	Document: Questions & Answers extract - SPOR and XEVMPD status update webinar 9 July 2025	New
28/07/2025	Medicine: Opzelura	Updated
28/07/2025	Medicine: Xofigo	Updated
28/07/2025	Medicine: Libmeldy	Updated
28/07/2025	Page: Procurement	Updated
28/07/2025	Page: Paediatric medicines: applications and procedures	Updated

Date	Content	Status
28/07/2025	Document: Additional information - Applicant's clarifications following Paediatric Committee (PDCO) discussions or re-discussions	New
28/07/2025	Document: Response to Paediatric Committee request for supplementary information and modification of proposed PIP (RSI) - Re-submission following clock-stop	New
28/07/2025	Document: Key elements form: Applicant's proposal for a paediatric-investigation-plan opinion	Updated
28/07/2025	Document: Template for scientific document for paediatric investigation plan or product-specific waiver	Updated
28/07/2025	Document: Procedural advice on paediatric applications	Updated
28/07/2025	Medicine: Voriconazole Accord	Updated
28/07/2025	Page: COVID-19 vaccines: key facts	Updated
28/07/2025	Event: EMA workshop on primary efficacy endpoints for antivirals and monoclonal antibodies intended for the treatment of COVID-19 and influenza	Updated

NOTICE TO APPLICANTS

No updates since July 07th, 2025.

BFARM - PHARMAKOVIGILANZ (SPECIFIC FOR GERMANY)

Date	Title
01.08.2025	Informationen zu Rote-Hand-Briefen und Informationsbriefen Das Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) veröffentlicht neue Hinweise zu anstehenden Rote-Hand-Briefen und Informationsbriefen.

BFARM – MEDIZINPRODUKTE (SPECIFIC FOR GERMANY)

Date	Title
30.07.2025	Erreichbarkeit der zuständigen Behörden der Länder sowie der zuständigen Bundesoberbehörden und der zuständigen Dienststelle der Bundeswehr zur Meldung von Risiken aus Medizinprodukten "außerhalb der Dienstzeit"

PEI - VIGILANZ (SPECIFIC FOR GERMANY)

No updates since May 22nd, 2025.

PHARMEUROPA TEXTS FOR COMMENT

Information on Pharmedeuropa updates will be presented quarterly.

Trotz regelmäßiger Aktualisierung und sorgfältiger Überwachung der Veröffentlichungen können wir keine Haftung oder Garantie für die Aktualität, Richtigkeit und Vollständigkeit der hier bereitgestellten Informationen übernehmen.
Dieser Newsletter enthält Links zu anderen Websites. Trotz sorgfältiger inhaltlicher Kontrolle übernehmen wir keine Haftung für die Inhalte externer Links. Für den Inhalt der verlinkten Seiten sind ausschließlich deren Betreiber verantwortlich.

Despite regular updating and careful monitoring of the publications, we cannot take any responsibility or guarantee for the topicality, correctness and completeness of the information provided here.
This Newsletter contains links to other websites. Despite careful control of the content we would like to point out that we are not liable for the contents of external web links. The editors of the respective websites are fully responsible for their contents.